Inactive Instrument

NattoPharma ASA

NATTO

NO0010289200

NattoPharma : Financial calendar

April 08, 2021 at 02:22 am EDT

Financial calendar for NattoPharma ASA

FINANCIAL YEAR 2021

14.07.2021 - Half-yearly Report
30.04.2021 - Annual Report
26.05.2021 - Annual General Meeting

26.01.2022 - Quarterly Report - Q4



Q1 and Q3 trading updates will be published respectively on May 12, 2021 and
November 3, 2021.


This information is published pursuant to the requirements set out in the
Continuing obligations.

Click here for more information

Latest news about NattoPharma ASA

NattoPharma : Files for Delisting from Euronext Expand	21-06-15	MT
NattoPharma : Lesaffre to Acquire Remaining Shares in NattoPharma	21-06-09	MT
NattoPharma : France's Lesaffre To Launch Compulsory Offer To Buy Remaining NattoPharma Shares	21-06-09	MT
NattoPharma : France's Lesaffre Completes Acquisition of NattoPharma	21-05-21	MT
NattoPharma : Lesaffre to Proceed with Squeeze Out of NattoPharma Shares Following Mandatory Offer	21-05-19	MT
NattoPharma : Lesaffre Secures 98% Stake In NattoPharma as Mandatory Offer Period Ends	21-05-18	MT
Compagnie Des Levures Lesaffre completed the acquisition of remaining 23% stake in NattoPharma ASA (OB:NATTO)	21-05-17	CI
NattoPharma : Lesaffre Launches Mandatory Offer For NattoPharma	21-04-20	MT
Compagnie Des Levures Lesaffre SA launched a mandatory offer to acquire remaining 23% stake in NattoPharma ASA (OB:NATTO) for approximately NOK 170 million.	21-04-18	CI
NattoPharma : Lesaffre Completes Settlement of All NattoPharma Options Pursuant to Takeover	21-04-13	MT
NattoPharma : Lesaffre Closes Voluntary Offer to Buy NattoPharma Shares	21-03-29	MT
NattoPharma ASA Terminates Contract with Norne Securities AS	21-03-26	CI
NattoPharma : Wins 76% Valid Acceptances For $85 Million Compagnie des Levures Lesaffre Offer	21-03-24	MT
NattoPharma : Lesaffre's NattoPharma Takeover Voluntary Offer Period Ends	21-03-23	MT
Compagnie Des Levures Lesaffre SA completed the acquisition of 76.43% stake in NattoPharma ASA (OB:NATTO) from Synergia Sciences Pvt. Ltd. and others for approximately NOK 560 million.	21-03-22	CI
NattoPharma ASA (OB:NATTO) completed the acquisition of an additional 41.31% minority stake in Kaydence Pharma AS for NOK 11.4 million.	21-03-22	CI
NattoPharma : Lesaffre Takeover of NattoPharma Gets Norwegian Competition Authority Clearance	21-03-12	MT
NattoPharma : French Suitor Lesaffre Submits Voluntary Cash Offer	21-03-09	MT
NattoPharma : Lesaffre's Takeover Bid for NattoPharma Achieves Minimum Acceptance Level	21-03-02	MT
Transcript : NattoPharma ASA, Q4 2020 Earnings Call, Feb 17, 2021	21-02-17
Nattopharma Asa Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-16	CI
NattoPharma : Lesaffre Offers to Buy NattoPharma in $75 Million Deal	21-02-15	MT
NattoPharma ASA (OB:NATTO) made an offer to acquire the remaining 45.9% stake in Kaydence Pharma AS for NOK 12.7 million.	21-02-14	CI
Compagnie Des Levures Lesaffre SA made a tender offer to acquire NattoPharma ASA (OB:NATTO) from Synergia Sciences Pvt. Ltd. and others for approximately NOK 740 million.	21-02-14	CI
Nattopharma & Cardiovascular Research Institute Maastricht Renew Long-Standing Vitamin K2 Research Partnership	20-12-01	CI

Nattopharma ASA is a Norway-based biotechnology company, which sells and develops products containing natural vitamin K2. The Company markets its products under its own trademark MenaQ7, principally in Europe and North America. MenaQ7 is provided either as powder or as an oil solution, and is used in stand-alone form, in complex dietary products and as additives to functional products. Nattopharma ASA offers contract manufacturing of dietary products, biochemical tests, marketing and sales support services. It provides its products primarily to the healthcare, supplement and functional food markets. The Company has an alliance with VitaK BV, at the Cardiovascular Research Institute (CARIM) at the University of Maastricht in the Netherlands.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+31.16%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.21%	244B
ROCHE HOLDING AG	-4.62%	208B
NOVARTIS AG	+9.85%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals